Company: INSP
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001609550-25-000032
Chunk: 55

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 55
---
)%(6,628)(11,610)4,982 (42.9)%Income (loss) before income taxes(2,332)10,846 (13,178)(121.5)%1,827 1,491 336 22.5 %Income taxes1,260 1,053 207 19.7 %2,427 1,703 724 42.5 %Net income (loss)$(3,592)$9,793 $(13,385)(136.7)%$(600)$(212)$(388)183.0 %

Comparison of the Three Months Ended June 30, 2025 and 2024

Revenue

Revenue increased $21.2 million, or 10.8%, to $217.1 million for the three months ended June 30, 2025 compared to $195.9 million for the three months ended June 30, 2024. These results reflect an increase in sales of our Inspire system of $19.3 million in the U.S. and an increase of $1.9 million outside of the U.S. compared to the same prior year period. Overall revenue growth was primarily due to increased market penetration, and, we believe, increased physician and patient awareness of our Inspire system, partially offset by ENT surgeon capacity constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.

Revenue information by region is summarized as follows:Three Months Ended June 30,20252024ChangeAmount% of RevenueAmount% of Revenue$%(in thousands, except percentages)United States$207,150 95.4 %$187,808 95.9 %$19,342 10.3 %All other countries9,936 4.6 %8,077 4.1 %1,859 23.0 %Total revenue$217,086 100.0 %$195,885 100.0 %$21,201 10.8 %

Revenue generated in the U.S. was $207.2 million for the three months ended June 30, 2025, an increase of $19.3 million, or 10.3%, compared to the three months ended June 30, 2024. Revenue growth in the U.S. was primarily due to increased market penetration, and